Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

mpany implemented a one-for-ten reverse split of all outstanding shares of its common stock and a corresponding decrease in the number of shares of authorized common stock. Share and per share amounts contained herein are provided on a post-split basis.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to c
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
(Date:7/23/2014)... Emirates (UAE) (PRWEB) July 23, 2014 ... recently announced that its biobanking project, Provia ... Ph.D. to its growing Advisory Board. Scott Wolf ... pleased to have Dr. Vaught onboard with Provia’s ever-expanding ... and expertise that Provia’s management team brings to this ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4
... YORK, June 8, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0548785/Future-of-White-Biotechnology-in-China.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... referred to the third wave in biotechnology, ...
... 7, 2011 Vaxart, Inc., a San Francisco biotechnology company ... I clinical trial. This is the first clinical study evaluating ... The trial site is in the United States. ... is demonstrated with one vaccine, we can expect that later ...
... 7, 2011 Infrared Systems International (OTCBB: IFRS) is pleased ... pilot study of its NatuRx™ HIV/AIDS treatment and will push ... AquaLiv concluded a pilot study with two HIV/AIDS patients ... of the first reported AIDS victims on June 5th, 1981. ...
Cached Biology Technology:Reportlinker Adds Future of White Biotechnology in China 2Reportlinker Adds Future of White Biotechnology in China 3Reportlinker Adds Future of White Biotechnology in China 4Reportlinker Adds Future of White Biotechnology in China 5Vaxart Begins First Oral Vaccine Clinical Trial 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 3
(Date:7/24/2014)... brewery has its own microbial terroir, meaning the microbial ... found in the product, creating the final flavor according ... Applied and Environmental Microbiology . This is the ... a sake brewery. , Many sake makers inoculate ... A. Mills of the University of California, Davis, but ...
(Date:7/24/2014)... cleanup experts gathered at NJIT this week for an ... the U.S. Environmental Protection Agency (EPA) to dredge toxic ... River. , The EPA has called the plan, which ... and capping sections of the riverbed, one of the ... would be dredged and disposed off-site. , "We need ...
(Date:7/24/2014)... research into the potato genes that best adapt to ... in rainfall and increased extremes of hot and cold ... in order to create new potato varieties that will ... seeking to find out how the current potato varieties ... higher and lower temperatures. , This research is part ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2
... Mich.---By mimicking the structure of the silk moth,s antenna, ... better nanopore---a tiny tunnel-shaped tool that could advance understanding ... A paper on the work is newly published ... headed by Michael Mayer, an associate professor in the ...
... developed by researchers in Temple University,s College of Science ... cancer. The leptin receptor antagonist peptide, developed by ... attractive option for triple negative breast cancer treatment, especially ... their findings online in the European Journal of ...
... environmental researchers from across North America have been ... Based at Stanford University,s Woods Institute for the ... 1998 to help academic scientists make their knowledge ... program selects up to 20 mid-career academic environmental ...
Cached Biology News:Silk moth's antenna inspires new nanotech tool with applications in Alzheimer's research 2New peptide could be effective treatment for triple negative breast cancer 220 researchers selected as 2011 Leopold Leadership Fellows 220 researchers selected as 2011 Leopold Leadership Fellows 320 researchers selected as 2011 Leopold Leadership Fellows 4
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... electronic from BRAND adds ergonomics and ... the only electronic, motor-driven repeating pipette ... including BRAND PD-Tip syringe tips, Eppendorf ... Tips,and VWRbrand Combi-Syringes. Select virtually any ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Biology Products: